BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 1,086%

TORONTO, ONTARIO--(Marketwired - Sept. 17, 2015) -

Editors Note: There is a photo associated with this press release.

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that Canadian Business and PROFIT today named BioSyent to the 27^th annual PROFIT 500, the definitive ranking of Canada's Fastest-Growing Companies. Published in the October issue of Canadian Business and at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their five-year revenue growth.

Based on a five-year revenue growth rate of 1,086% (2009-2014), BioSyent ranked 64th on the 2015 PROFIT 500 list. This is the third consecutive year that BioSyent has been named to the PROFIT 500 list and marks a significant increase in the Company's five-year revenue growth rate, from 608% on last year's list to 1,086% on this year's list.

"We are pleased to be named to the PROFIT 500 list again," commented René Goehrum, President and CEO of BioSyent. "We continue to build our brand portfolio with innovative products that will fuel our growth for years to come."

"The PROFIT 500 represent the highest tier of entrepreneurialism in Canada," says James Cowan, Editor-in-chief of PROFIT and Canadian Business. "They should be lauded for the positive economic contributions they've made to their communities - and the entire country. They are examples of what can be accomplished with innovation, discipline and determination."

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 13,966,195 shares issued and outstanding.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

To view the photo associated with this press release, please visit the following link: http://www.marketwire.com/library/20150916-PROFIT500L.jpg